Compare ADMA Biologics Inc (ADMA) vs Tapestry, Inc. (TPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Tapestry, Inc. — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while Tapestry, Inc. trades at $141.16 (market cap $29.40B). The key difference: Tapestry, Inc. is far larger — about 13.8× ADMA Biologics Inc's market cap, and Tapestry, Inc. pays a 1.1% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TPR | |
|---|---|---|
Market Cap | $2.13B | $29.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $160.49 |
52-Week Low | $7.60 | $92.20 |
Enterprise Value | $2.20B | $32.25B |
Dividend Yield | — | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
TPR trades at $146.3, up 1.45% today, with a bullish technical signal and strong analyst support. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.66 exceeding the $1.30 estimate. The company maintains high profitability margins, including a 76.18% gross margin and 55.74% ROE, though net income margin declined to 8.44% in 2025. Positive news highlights digital growth and Gen Z engagement, with a consensus price target of $184.14 implying significant upside.
Outlook is positive given earnings momentum and analyst optimism, but risks include high debt levels, volatile cash flows, and competitive pressures in the luxury retail sector. The stock's elevated P/E of 44.36 requires sustained growth to justify valuation, while institutional ownership trends and insider activity should be monitored for confirmation of bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
